Vaccines

GSK and CureVac Enter into Licensing Agreement

July 04, 2024

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

Highlighting Personalized mRNA-Based Vaccines for Pancreatic Cancer (ASGCT 2024)

May 25, 2024

In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.

The Making of mRNA

April 26, 2024

A tidal wave of questions floats the need for more upstream automation.

Increasing mRNA Product Stability with Lyophilization

April 24, 2024

Developing freeze-drying processes requires patience and deep product and process understanding.

Navigating an Uncertain Regulatory Environment for mRNA-based Products

April 23, 2024

Regulations for mRNA products are evolving as the market for mRNA expands.

Evaluating the Partnership between mRNA and LNPs

April 16, 2024

The LNP success in mRNA vaccines leads to their establishment as a standard in mRNA delivery.

Dr. Reddy’s Partners with Sanofi Healthcare India to Distribute Vaccines

March 29, 2024

Dr. Reddy’s has gained exclusive rights to promote and distribute Sanofi’s vaccines in India.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

March 07, 2024

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

AstraZeneca Completes Acquisition of Icosavax

February 21, 2024

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

A Platform for mRNA Platforms

January 11, 2024

Regulators from around the world will gather to help shape the mRNA and RNA therapeutics landscape at an exceptional April 2024 Washington, D.C. convocation.